FilingSEC EDGAR6-K
Evaxion Announces New Phase 2 Data for Cancer Vaccine EVX-01
· SEC accepted
StagePhase 2
Filing content
Evaxion announced new biomarker data from its phase 2 trial of personalized cancer vaccine EVX-01, demonstrating potent T-cell immune responses. The data will be presented at the SITC 2026 Annual Meeting.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…